Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
7 hedge funds and large institutions have $8.88M invested in Celyad Oncology SA American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
4% less capital invested
Capital invested by funds: $9.23M → $8.88M (-$351K)
22% less funds holding
Funds holding: 9 → 7 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$506K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$40.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$110K |
| 2 |
Millennium Management
New York
|
-$35.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.25K |
| 4 |
Morgan Stanley
New York
|
-$2.69K |
CYAD Hedge Fund Activity: Q3 2020 in Review
7 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2020, worth a combined $8.88M — down 3.8% from $9.23M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYAD and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Victory Capital Management, adding an estimated $506K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $110K sold.
- 7 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2020, down from 9 in Q2 2020.
- Funds reported $8.88M of Celyad Oncology SA American Depositary Shares stock for Q3 2020, down 3.8% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2020 and 2 closed out, a net change of -2 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2020 was Victory Capital Management, an estimated $506K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2020 was Renaissance Technologies, an estimated $110K sold.
Based on aggregated 13F filings for Q3 2020.